Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) shares shot up 0.1% on Monday . The company traded as high as $9.75 and last traded at $9.75. 155 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 3,787 shares. The stock had previously closed at $9.74.
Telix Pharmaceuticals Trading Up 0.1%
The firm has a fifty day simple moving average of $9.51 and a 200-day simple moving average of $8.64.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
See Also
- Five stocks we like better than Telix Pharmaceuticals
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
